Key facts
- Inopharma’s last known valuation is $4.2M (Apr 2026).
- It has raised $10K; the latest was Early Stage VC in Jun 2027.
- Notable investors include Tech Incubator Program for Startup, Center for Creative Economy and Innovation, A-One AC, Find Us, InfoBank — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Inopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Inopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inopharma
Developer of hemostatic medical devices designed to control bleeding in emergency and clinical environments. The company offers products such as hemostatic agents, soft tissue strengtheners, and anti-adhesion agents, enabling healthcare providers and users to rapidly stop bleeding in surgical, trauma, and first-aid situations.
- Sector
- Healthcare
- HQ
- Daegu, South Korea
- Founded
- 2023
- Employees
- 7
- Website
- innophm.com/
- Ownership
- Privately Held (backing)
Inopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inopharma in its N-PORT filings yet. We sweep new filings monthly.